# Q3-2026 Execution Summary: 5 Sequential + Parallel Initiatives

**Period:** July 1 – September 30, 2026  
**Critical Decision Point:** August 21, 2026 (FDA Premarket Go/No-Go)  
**Compliance Target:** Score 89/100 (from 87/100 Q2 baseline)  
**Status:** Ready for launch

---

## Initiative Roadmap at a Glance

| # | Initiative | Owner | Duration | Priority | Status | Decision |
|---|-----------|-------|----------|----------|--------|----------|
| 1 | ISO 14971 FMEA Formalization | Timothy H. | 4 weeks | HIGH | 📋 Detailed plan ready | Unblocks design controls |
| 2 | EHR Integration Framework | Eng Team | 6 weeks | HIGH | 📋 Detailed plan ready | Unblocks clinical deployment |
| 3 | Advanced Observability Phase 2 | Platform Eng | 5 weeks | MEDIUM | 📋 Detailed plan ready | Improves production visibility |
| 4 | FDA Premarket Readiness Assessment | Timothy H. | 3 weeks | CRITICAL | 📋 Detailed plan ready | **GO/NO-GO Decision** |
| 5 | Third-Party Dependency Audit | Timothy H. | 2 weeks | MEDIUM | 📋 Detailed plan ready | Closes supply chain risk |

---

## Initiative 01: ISO 14971 Risk Management Formalization

**Goal:** Establish baseline FMEA with 18–25 hazard modes; formalize quarterly risk review cycle

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 4 weeks (July 1–28)  
**Actions:**
- Conduct risk analysis workshop (2 hours, identify hazard modes)
- Document FMEA baseline (18–25 modes with risk scores)
- Define mitigation strategies for high-risk modes
- Create quarterly review schedule (Jul–Dec 2026)

**Success:** Baseline FMEA completed; risk acceptance signed by stakeholders

**Deliverables:**
- `dhf/risk/fmea-baseline.xlsx` (FMEA spreadsheet)
- `dhf/risk/fmea-process.md` (ISO 14971 §7 process documentation)
- Risk acceptance form (signed)
- Quarterly review schedule (calendar invites)

**Effort:** ~10 hours (4 weeks calendar)

---

## Initiative 02: EHR Integration Framework

**Goal:** Define FHIR US Core 6.1 bidirectional mapping; validate integration via sandbox testing

**Owner:** Engineering Team  
**Duration:** 6 weeks (July 1 – August 15)  
**Actions:**
- Document FHIR resource mapping (5+ types: Patient, Observation, DocumentReference, DiagnosticReport, Encounter)
- Implement bidirectional data transformation layer
- Create 10+ integration validation tests
- Test against Epic/Cerner FHIR sandbox
- Verify OAuth 2.0 / SMART on FHIR compliance

**Success:** Sandbox EHR connectivity verified; integration tests passing

**Deliverables:**
- `docs/ehr-integration/FHIR_MAPPING.md` (specification)
- Integration code (mapping engine, FHIR API endpoints)
- Integration test suite (10+ tests)
- Sandbox connectivity report

**Effort:** ~22 hours (6 weeks calendar)

---

## Initiative 03: Advanced Observability Phase 2

**Goal:** Deploy persistent trace storage (Tempo); add service mesh instrumentation; create observability dashboards

**Owner:** Platform Engineering  
**Duration:** 5 weeks (July 8 – August 19)  
**Actions:**
- Deploy Grafana Tempo (30+ day trace retention)
- Configure OpenTelemetry + OTLP ingestion
- Implement service mesh sidecar instrumentation
- Create service dependency graph dashboard
- Build distributed trace detail dashboards
- Deploy sample-based tracing (100% errors, 1% success, 10% high-latency)

**Success:** Traces stored 30+ days; service dependencies visible; sampling rules effective

**Deliverables:**
- Tempo deployment (infrastructure-as-code)
- Grafana dashboards (service dependency graph, trace detail)
- `docs/observability/TRACE_SAMPLING.md` (sampling strategy)

**Effort:** ~18 hours (5 weeks calendar)

---

## Initiative 04: FDA Premarket Readiness Assessment — CRITICAL DECISION POINT

**Goal:** Comprehensive readiness evaluation; formal GO/NO-GO decision on FDA device pathway

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 3 weeks (August 1–21)  
**Actions:**
- Technical review (IEC 62304 traceability, SBOM/VEX, provenance)
- Cybersecurity assessment (NIST SP 800-218 SSDF v1.1)
- 21 CFR Part 11 compliance verification
- Legal review (IP, regulatory precedent, classification)
- Business case (resource commitment, timeline)
- Final readiness assessment + stakeholder vote

**Go Criteria (ALL must be met):**
- ✅ IEC 62304 traceability ≥95%
- ✅ Compliance score ≥87/100
- ✅ Cybersecurity assessment passed
- ✅ Legal sign-off (no blockers)
- ✅ 2.5+ FTE resource commitment secured

**Decision Date:** August 21, 2026  
**Decision Committee:** Compliance Officer, CFO, CTO, CEO (vote required)

**Outcomes:**

**Option A: GO (Proceed with FDA Pathway)**
- Assemble premarket package (510(k) or PMA)
- Engage FDA regulatory counsel
- Q4 2026 submission target
- Year 3 roadmap: FDA regulatory pathway

**Option B: NO-GO (Non-Device Platform Strategy)**
- Pivot to TEFCA/QHIN healthcare IT
- Pursue non-clinical deployment model
- Year 3 roadmap: Platform expansion (EHR integration, multi-vendor)

**Deliverables:**
- `dhf/FDA_PREMARKET_READINESS_REPORT.pdf` (formal assessment)
- Device classification determination (510(k) vs. PMA)
- Board presentation (go/no-go recommendation)
- Year 3 roadmap (conditional on decision)

**Effort:** ~12 hours (3 weeks calendar)

---

## Initiative 05: Third-Party Dependency Audit

**Goal:** Audit all clinical repo dependencies; classify (approved/review/prohibited); close supply chain risk gap

**Owner:** Timothy Hartzog (Compliance Officer)  
**Duration:** 2 weeks (September 1–14)  
**Actions:**
- Inventory dependencies (PedNeoSim.jl, pediatric-cds, audit-service)
- Classify each: Approved (BAA), Requires-Review, Prohibited (GPL/unmaintained)
- Risk assess high-risk packages (zero-days, unmaintained)
- Create dependency policy (policies/dependencies.md)
- Develop remediation plan for non-compliant dependencies

**Success:** 100% of dependencies classified; ≥90% Tier 1/2 (approved/review); policy published

**Deliverables:**
- `compliance-metrics/dependency-inventory-q3-2026.csv` (full tree)
- `policies/dependencies-classified.xlsx` (classification matrix)
- `compliance-metrics/dependency-risk-assessment.md` (risk analysis)
- `policies/dependencies.md` (published policy)

**Effort:** ~8 hours (2 weeks calendar)

---

## Parallel Execution Timeline

```
July 1 ──────────────────────────────── September 30

Initiative 1 (FMEA)
  ├─ Weeks 1–2: Risk analysis workshop
  ├─ Weeks 2–4: FMEA documentation
  └─ Jul 1–28 (parallel with 2–5)

Initiative 2 (EHR Integration)
  ├─ Weeks 1–2: FHIR mapping specification
  ├─ Weeks 2–4: Implementation
  ├─ Weeks 4–6: Testing & validation
  └─ Jul 1 – Aug 15 (parallel with all)

Initiative 3 (Observability)
  ├─ Weeks 1–2: Tempo deployment
  ├─ Weeks 2–3: Instrumentation
  ├─ Weeks 4–5: Dashboards
  └─ Jul 8 – Aug 19 (parallel with all)

Initiative 4 (FDA Readiness)
  ├─ Week 1: Technical review
  ├─ Week 2: Regulatory alignment
  ├─ Week 3: Final assessment + vote
  └─ Aug 1–21 (CRITICAL DECISION: Aug 21)

Initiative 5 (Dependency Audit)
  ├─ Weeks 1–2: Inventory & classification
  ├─ Weeks 2–3: Risk assessment
  ├─ Weeks 3–4: Policy & remediation plan
  └─ Sep 1–14 (after Q3 decision point)

Aug 21: FDA GO/NO-GO DECISION
  → Year 3 roadmap conditional on outcome

Sep 30: Q3 Close
  → Compliance score 89/100 (target)
  → Q4 roadmap finalized
  → Q1 2027 preparation
```

---

## Critical Path & Dependencies

**Critical Path (blocks other work):**
1. Initiative 1 (FMEA) — Must complete by Jul 28 to inform Initiative 4 risk assessment
2. Initiative 4 (FDA Readiness) — Must complete by Aug 21 (decision gate)
3. Initiative 2 (EHR Integration) — Should complete by Aug 15 for clinical deployment path

**Independent Parallel Work:**
- Initiative 3 (Observability) — Can proceed independently; no blockers
- Initiative 5 (Dependency Audit) — Can proceed independently after Aug 21 decision

---

## Weekly Checkpoints

**July 1 (Week 1 start):** All 5 initiatives launch
- Initiative 1: Risk analysis workshop conducted
- Initiative 2: FHIR mapping specification started
- Initiative 3: Tempo deployment planning
- Initiative 4: Technical review started
- Initiative 5: Dependency inventory started

**July 15 (Week 3 checkpoint):**
- Initiative 1: FMEA 50% documented
- Initiative 2: Mapping specification draft complete
- Initiative 3: Tempo deployed, instrumentation starting
- Initiative 4: Technical review complete, regulatory alignment starting
- Initiative 5: Classification 50% complete

**August 1 (Week 5 checkpoint):**
- Initiative 1: FMEA complete, quarterly review schedule published ✅
- Initiative 2: Implementation 50% complete
- Initiative 3: Dashboards starting
- Initiative 4: Final assessment phase (CRITICAL)
- Initiative 5: Held pending Aug 21 decision

**August 21 (CRITICAL DECISION):**
- Initiative 4: **GO/NO-GO DECISION VOTE**
  - Option A: Proceed to premarket package (FDA pathway)
  - Option B: Pivot to TEFCA/QHIN non-device platform
- Year 3 roadmap conditional on outcome

**August 31 (Week 9 checkpoint):**
- Initiative 1: ✅ COMPLETE (FMEA formalized, quarterly reviews active)
- Initiative 2: ✅ Sandbox testing in progress; integration tests 80% complete
- Initiative 3: ✅ Observability dashboard live; sampling rules active
- Initiative 4: ✅ GO/NO-GO decision implemented; Year 3 roadmap updated
- Initiative 5: Starting (post-decision; can now proceed)

**September 14 (Week 13 checkpoint):**
- Initiative 5: ✅ COMPLETE (dependency audit, policy published)
- Remaining: Final verification & Q3 closure

**September 30 (Q3 end):**
- ✅ All 5 initiatives completed (or conditionally deferred based on Aug 21 decision)
- ✅ Compliance score target 89/100 achieved
- ✅ Q3-2026 review meeting scheduled (October 1)
- ✅ Year 3 roadmap finalized (conditional on FDA decision)

---

## Success Criteria (Q3 Completion)

✅ **Initiative 1:** Baseline FMEA completed (18–25 modes); quarterly review cycle operationalized  
✅ **Initiative 2:** FHIR mapping specification complete; 10+ integration tests passing; sandbox connectivity verified  
✅ **Initiative 3:** Tempo deployed; service dependency dashboards live; tracing sampling active  
✅ **Initiative 4:** FDA premarket readiness assessment complete; formal GO/NO-GO decision made  
✅ **Initiative 5:** All dependencies classified; policy published; remediation plan for non-compliant  

**Overall Q3 Target:** Compliance score 89/100 (from 87/100 Q2 baseline)

---

## Resource Allocation

| Role | Total Q3 Effort | Initiatives |
|------|-----------------|-------------|
| Timothy H. (Compliance Officer) | ~30 hours | 1, 4, 5 |
| Engineering Team | ~40 hours | 2, 3 |
| All Hands (Decision Committee) | ~4 hours | 4 (Aug 21 vote) |
| **Total** | **~74 hours** | **All 5** |

**Calendar Time:** 13 weeks (July 1 – September 30)  
**FTE Effort:** ~1.8 weeks (one full-time person for entire Q3)  
**Parallel Execution Efficiency:** 74 hours ÷ 13 weeks ÷ 40 hrs/week = ~1.4 FTE-weeks needed, achieved via parallelization

---

## Strategic Significance

### Initiative 1 (FMEA)
- Enables design controls (required for FDA Class A/B devices)
- Informs risk-based testing (Initiative 3 observability, chaos testing from Q2)
- Establishes ISO 14971 annual review process

### Initiative 2 (EHR Integration)
- Unblocks clinical deployment pathway
- Enables multi-facility rollout (EHR interoperability)
- Required for healthcare IT platform (if NO-GO on device pathway)

### Initiative 3 (Observability)
- Improves production monitoring (required for clinical use)
- Enables DORA metrics tracking (deployment frequency, lead time, reliability)
- Supports FDA post-market surveillance (adverse event detection)

### Initiative 4 (FDA Decision)
- **CRITICAL BUSINESS DECISION** determining Years 3–5 strategy
- Device pathway: FDA submission, QMS, design controls, post-market
- Non-device pathway: Healthcare IT expansion, TEFCA/QHIN, platform scaling

### Initiative 5 (Dependency Audit)
- Closes SSDF v1.1 supply chain risk gap
- Required for FDA premarket submission (software security pedigree)
- Enables ISO 13485 supplier management compliance

---

## Next Review

**Q3-2026 Midpoint Checkpoint:** August 15, 2026
- Verify progress on all 5 initiatives (especially critical paths 1, 2, 4)
- Flag any blockers or risks
- Adjust timeline if needed

**Q3-2026 Closure Review:** October 1, 2026
- Final compliance scorecard (target 89/100)
- Lessons learned (what worked, what didn't)
- Year 3 roadmap finalized (conditional on FDA decision)
- Year 3 kickoff preparation

**FDA Premarket Decision Committee Meeting:** August 21, 2026
- Formal vote: GO (FDA pathway) vs. NO-GO (TEFCA/QHIN pathway)
- Board-level presentation + stakeholder alignment
- Year 3 strategic direction determined

---

## Commitment & Approval

**Q3-2026 Execution Plan approved by:**

- **Timothy Hartzog** — Compliance Officer (Initiatives 1, 4, 5)
- **Engineering Lead** — (Initiatives 2, 3)
- **Executive Sponsor** — Strategic oversight (Initiative 4 decision gate)

**Approval Date:** May 15, 2026 (today)  
**Effective Start:** July 1, 2026  
**Target Completion:** September 30, 2026  
**Critical Decision Date:** August 21, 2026

---

## Links to Detailed Plans

- **Initiative 01:** `copilot-tasks/q3-2026-initiatives/initiative-01-iso14971-fmea-formalization.md`
- **Initiative 02:** `copilot-tasks/q3-2026-initiatives/initiative-02-ehr-integration-framework.md`
- **Initiative 03:** `copilot-tasks/q3-2026-initiatives/initiative-03-advanced-observability-phase2.md`
- **Initiative 04:** `copilot-tasks/q3-2026-initiatives/initiative-04-fda-premarket-readiness.md`
- **Initiative 05:** `copilot-tasks/q3-2026-initiatives/initiative-05-third-party-dependency-audit.md`

---

**Ready for Q3-2026 execution. All initiatives approved. Launch date: July 1, 2026.**

**CRITICAL BUSINESS DECISION: August 21, 2026 (FDA Go/No-Go Vote)**

